NewAmsterdam Pharma (NAMS) Research & Development (2023 - 2026)

NewAmsterdam Pharma (NAMS) has 4 years of Research & Development data on file, last reported at $38.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 15.07% year-over-year to $38.0 million; the trailing twelve-month figure through Mar 2026 stood at $135.1 million (down 12.12% YoY), and the FY2025 full-year result was $141.8 million, down 6.32% from the prior year.
• Research & Development slipped to $38.0 million in Q1 2026, from $38.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $44.8 million in Q1 2025 to a low of $27.5 million in Q2 2025.
• A 4-year average of $37.7 million and a median of $38.4 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development rose 11.76% in 2024 and declined 28.3% in 2025, its largest moves.
• Tracing NAMS's Research & Development over 4 years: stood at $41.3 million in 2023, then fell by 15.49% to $34.9 million in 2024, then grew by 10.6% to $38.6 million in 2025, then declined by 1.52% to $38.0 million in 2026.
• Business Quant data shows NAMS's Research & Development at $38.0 million in Q1 2026, $38.6 million in Q4 2025, and $31.0 million in Q3 2025.